# US 2010/0137229 A1 · Method Of Enhancing Lysosomal Alpha-Galactosidase A

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0137229 A1
- Document ID: US20100137229A1
- Status: Published application
- Kind: A1
- Application number: 12/624,026
- Filed: 2009-11-23
- Published: 2010-06-03
- Earliest claimed: 1998-06-01
- Assignees: Mount Sinai School of Medicine of New York University
- Inventors: Jian-Qiang Fan; Satoshi Ishii
- Web page: https://patentgrep.com/patent/US20100137229A1

## CPC

- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 31/7008: Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/12: of the kidneys
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 451/06: Oxygen atoms
- C12N 9/2465: {acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method of enhancing the activity of lysosomal α-Galactosidase A (α-Gal A) in mammalian cells and for treatment of Fabry disease by administration of 1-deoxy-galactonojirimycin and related compounds.

## Claims

### Claim 1

A method of enhancing the activity of lysosomal α-galactosidase
A in mammalian cells comprising administering an effective amount of a compound selected from the group consisting of 2,5-dideoxy-2,5-imino-D-mannitol, 3,4-diepi-α-homonojirimycin, 5-O-α-D-galactopyranosyl-α-homonojirimycin, 1-deoxygalactonojirimycin, 4-epi-fagomine, calystegine A3, calystegine B2, and calystegine B3, and N-alkyl derivatives thereof.

### Claim 2 (depends on 1)

The method of claim 1 wherein the lysosomal α-galactosidase A is a mutant form which is present in patients with Fabry disease.

### Claim 3 (depends on 1)

The method of claim 1 wherein said cells are human cells.

### Claim 4 (depends on 3)

The method of claim 3 wherein said cells are the cells of a patient with Fabry disease.

### Claim 5

A method of treating Fabry disease comprising administering an effective amount of a compound selected from the group consisting of 2,5-dideoxy-2,5-imino-D-mannitol, 3,4-diepi-α-homonojirimycin, 5-O-α-D-galactopyranosyl-α-homonojirimycin, 1-deoxygalactonojirimycin, 4-epi-fagomine, calystegine A3, calystegine B2, and calystegine B3, and N-alkyl derivatives thereof.

### Claim 6 (depends on 5)

The method of claim 5 wherein said compound is 1-deoxygalactonojirimycin or 3,4-diepi-α-homonojirimycin.

### Claim 7 (depends on 6)

The method of claim 6 wherein said compound is 1-deoxygalactonojirimycin.

### Claim 8

A method of enhancing the activity of lysosomal α-galactosidase A in mammalian cells comprising administering an effective amount of a compound of the formula
wherein
R1 represents H, —CH2— or CH2OH;
R2 represents H, OH or —O-galactose;
R3 and R4 independently represent H, or OH;
R5 represents H, or —CH2—;
R6 represents CH2OH, or OH; and
R1 represents H or an alkyl group containing 1-3 carbon atoms, provided that when either R1 or R5 is —CH2—, they are identical and are linked to form a second ring structure.

### Claim 9

A method of treating Fabry disease comprising administering an effective amount of a compound of the formula
wherein
R1 represents H, —CH2— or CH2OH;
R2 represents H, OH or —O-galactose;
R3 and R4 independently represent H, or OH;
R5 represents H, or —CH2—;
R6 represents CH2OH, or OH; and
R7 represents H or an alkyl group containing 1-3 carbon atoms, provided that when either R1 or R5 is —CH2—, they are identical and are linked to form a second ring structure.
